REG - Tissue Regenix Group - Update re. proposed cancellation of shares

Tissue RegenixAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251208:nRSH6180Ka&default-theme=true

RNS Number : 6180K  Tissue Regenix Group PLC  08 December 2025

Tissue Regenix Group plc

('Tissue Regenix', the 'Group' or the 'Company')

 

Update re. proposed cancellation of shares

 

Tissue Regenix (AIM: TRX), the regenerative medical devices company, provides
a further update on the proposed cancellation of its shares.

 

Further to the announcement of 4 December 2025, the Company expects to remain
solvent assuming that the Resolutions are passed at the General Meeting on 22
December 2025 and the initial £7.5m of the Secured Convertible Loan Note is
drawn down shortly thereafter.

 

However, in light of the ongoing financial challenges facing the Company and
continued uncertainty over its current trading position, the Board does not
believe it will be able to clarify Tissue Renegix's financial position with
any degree of certainty ahead of the proposed Cancellation date. As a result,
trading in the Ordinary Shares will remain suspended ahead of Cancellation on
7 January 2026.

 

There will be a matched bargain facility in place from 7 January 2026 for a
period of at least a year which will allow Shareholders to trade on a matched
bargain basis.

 

Unless otherwise defined, all capitalised terms used but not defined in this
announcement shall have the meaning given to them in the announcement made by
the Company on 4 December 2025.

 

For more information, please contact:

 

 Tissue Regenix Group plc
 Jay LeCoque, Executive Chairman                            via Walbrook PR

 Cavendish Capital Markets (Nominated Adviser and Broker)
 Geoff Nash/Giles Balleny/Edward Whiley                     Tel: +44 (0) 20 7466 5000

 Nigel Birks - Life Science Specialist Sales

 Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)                          Tel: +44 (0)20 7933 8780
 Alice Woodings / Lianne Applegarth                         Tissue Regenix@walbrookpr.com (mailto:TissueRegenix@walbrookpr.com)

 

 

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold that is not rejected by the patient's body and can
be used to repair diseased or damaged body structures. Current applications
address many crucial clinical needs in sports medicine, foot and ankle
injuries, and wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®. This
biotech company specialises in regenerative medicine and is dedicated to
developing high-quality, innovative tissue scaffolds to enhance healing
opportunities in defects created by trauma and disease. CellRight's human
tissue products may be used in spine, trauma, general orthopaedic, dental and
ophthalmological surgical procedures.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFSFEFWEISESE



            Copyright 2019 Regulatory News Service, all rights reserved